Good evening, ladies and gentlemen, and welcome to the Anika Therapeutics First Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]I will now like to turn the call over to Sylvia Cheung, Chief Financial Officer. Please proceed.

Thank you, Sadie. Good evening, everyone, and thank you for joining us. With me on the call today is Dr. Cheryl Blanchard, who was recently appointed President and Chief Executive Officer of Anika. I have worked with Cheryl for almost two years and closely alongside her over the past several months, during this highly unusual time externally and internally. I look forward to continuing to work with her and the rest of our management team to deliver progress towards our strategic plan.During today's call, Cheryl and I will review our first quarter 2020 financial results and key business highlights, which were summarized in our earnings release issued today. A copy of the earnings release is available on the Investor Relations section of our website at anikatherapeutics.com.In addition, a slide presentation is posted on our website in the Investors Relations section under the Events and Presentations tab. We invite you to take a moment now to open the file and follow the presentation along with us.Please turn to Slide #2. Before we begin, please remember that certain statements made during this conference call constitute forward-looking statements as defined in the Securities Exchange Act of 1934. These statements are based on our current beliefs and expectations, including statements with respect to impacts of the COVID-19 pandemic on Anika. These statements are subject to certain risks and uncertainties. The company's actual results could differ materially from any anticipated future results, performance or achievements. Please also see our SEC filings for more information about factors that could affect our results.Certain financial measures we will discuss on this call are non-GAAP financial measures. We believe that by providing these measures, helps investors gain a more complete understanding of our results and is consistent with how management views our financial performance. A reconciliation of these non-GAAP…

Thank you, Sylvia, and good evening. We hope that everyone joining us on this call remains safe and in good health during this difficult and unprecedented time. Whether at home or in the workplace, we have all been impacted by the effects of the COVID-19 pandemic and our hearts go out to everyone who has suffered personal hardship or loss. Our hearts also go out to the health care workers around the world, who are on the front lines selflessly fighting this global pandemic.As this is my first quarterly call since being named President and CEO, I would like to thank the Board of Directors for their support during the last several months and for their confidence in my leadership. As a Board member and then as interim CEO, I realized that I had a unique opportunity to leverage my past experiences to help guide Anika through its continued evolution.I have successfully led operational and commercial businesses through periods of significant growth, scaling, integration and even disruption. I am very excited and humbled to have been chosen to continue working with the Anika leadership team to drive the company's momentum and growth.As I considered taking on the CEO role permanently, I thought about Anika's tremendous opportunity: a company with products that address true unmet patient and market needs and the commercial engine to deliver significant value in attractive segments of the orthopedic market. I thought about Anika's strong culture of innovation, operational excellence and financial discipline. I also thought about the recent transformative acquisitions of Parcus and Arthrosurface and the tremendous growth opportunities they present.In short, over the last several months, I have come to appreciate that Anika presents an exceptional opportunity. Anika has a strong leadership team as well as talented and passionate employees. And I have the benefit…

Thank you, Cheryl. Please turn to Slide #6. I'd like to begin by reviewing our 3 new product categories for which we are reporting revenue, following the expansion of our product portfolio into therapies for joint preservation and restoration.First is the joint pain management family, which includes the human and animal viscosupplement products, including MONOVISC, CINGAL and ORTHOVISC. Second is the orthopedic joint preservation and restoration family, including TACTOSET, HYALOFAST and sports medicine surgical products from Parcus and Arthrosurface. And lastly, the other category, which includes legacy products, such as ophthalmology, advanced wound care and anti-adhesion surgical products.Please turn to Slide #7. Anika achieved record Q1 revenue despite the COVID-19 pandemic, which impacted our first quarter results. Total revenue for the first quarter of 2020 increased 43% year-over-year to $35.4 million compared to $24.7 million in the prior year. Revenue growth for the quarter was driven primarily by orthopedic joint preservation and restoration products due to the acquisitions of Parcus and Arthrosurface, which contributed a combined $6.8 million of revenue during the quarter.Further, our joint pain management portfolio delivered worldwide growth of 12% year-over-year. Domestic joint pain management revenue increased 7% year-over-year for the quarter, and international joint pain management revenue increased 36% year-over-year for the quarter.Cost of product revenue, R&D and SG&A expenses in the quarter were $34.7 million compared to $19.2 million in the first quarter of 2019. The cost of product revenue increased $6.9 million due to robust top line growth. It included $3 million of acquisition-related amortization expense.Selling, general and administrative expenses increased $6.8 million, which reflected $4.2 million of acquisition-related expenses in the first quarter. In addition, SG&A expenses also included increased selling and marketing expenses related to the two newly acquired companies, Parcus and Arthrosurface, that broad expanded sales commercial infrastructure to Anika.As I…

[Operator Instructions] I am showing no questions at this time. I would like to turn the conference back over to Sylvia Cheung.

Cheryl, we'll turn the call over to you for closing remarks.

Great, thanks, Sylvia. As you heard today and from merely all companies in recent weeks, this is certainly not a business-as-usual moment in time. There is simply no playbook for how to emerge safely and effectively from a global pandemic. However, I can assure you that Anika is positioned very well to weather the impact and emerge stronger than before, with renewed purpose and vision and an enhanced organizational structure that will enable us to deliver meaningful therapies to patients and value to shareholders.Thank you for your time today. We look forward to updating you as we continue to deliver progress on our strategic initiatives. Have a great evening, and please stay well.

Ladies and gentlemen, this concludes today's conference call. Thank you all for participating. You may now disconnect.